Cargando…

Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)

BACKGROUND: Standard intravenous (IV) paclitaxel is associated with hypersensitivity/toxicity. Alternative IV formulations have improved tolerability but still require frequent hospital visits and IV infusion. DHP107 is a novel oral formulation of paclitaxel that is approved in South Korea for the t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Sung-Bae, Seo, Jae Hong, Ahn, Jin-Hee, Kim, Tae-Yong, Kang, Seok Yun, Sohn, Joohyuk, Yang, Yaewon, Park, Kyong Hwa, Moon, Yong Wha, Lim, Seungtaek, Kang, Myoung Joo, Yoon, Koung Eun, Cho, Hyun Ju, Lee, Keun Seok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679020/ https://www.ncbi.nlm.nih.gov/pubmed/34925553 http://dx.doi.org/10.1177/17588359211061989

Ejemplares similares

A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer
por: Ryu, Min‐Hee, et al.
Publicado: (2017)

Tissue pharmacokinetics of DHP107, a novel lipid‐based oral formulation of paclitaxel, in mice and patients by positron emission tomography
por: Moon, Byung Seok, et al.
Publicado: (2021)

DHP23002 as a next generation oral paclitaxel formulation for pancreatic cancer therapy
por: Jang, Eunseo, et al.
Publicado: (2019)

DHP-Derivative and Low Oxygen Tension Effectively Induces Human Adipose Stromal Cell Reprogramming
por: Jee, Min Ki, et al.
Publicado: (2010)

Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy
por: Jung, Minkyu, et al.
Publicado: (2012)

Observational study for direct hemoperfusion therapy with polymyxin-B immobilized fibers (PMX-DHP) in patients with septic shock in Japan: PMX-DHP study group
por: Kase, Y, et al.
Publicado: (2009)

Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)
por: Sim, Sung Hoon, et al.
Publicado: (2022)

A Genetic Screen for Dihydropyridine (DHP)-Resistant Worms Reveals New Residues Required for DHP-Blockage of Mammalian Calcium Channels
por: Kwok, Trevor C. Y., et al.
Publicado: (2008)

Correction: A Genetic Screen for Dihydropyridine (DHP)-Resistant Worms Reveals New Residues Required for DHP-Blockage of Mammalian Calcium Channels
por: Kwok, Trevor C. Y., et al.
Publicado: (2009)

Is it true that PMX-DHP can improve lung oxygenation?
por: Ikeda, T, et al.
Publicado: (2003)

Effect of PMX-DHP according to differences in infection site
por: Ikeda, T, et al.
Publicado: (2001)

Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
por: Sim, Sung Hoon, et al.
Publicado: (2019)

Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
por: Kim, Ji-Yeon, et al.
Publicado: (2019)

An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer
por: Park, In Hae, et al.
Publicado: (2017)

BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy
por: Kim, Sung-Bae, et al.
Publicado: (2019)

miR-107 Enhances the Sensitivity of Breast Cancer Cells to Paclitaxel
por: Ma, Changpo, et al.
Publicado: (2019)

Tocilizumab and PMX-DHP have efficacy for severe COVID-19 pneumonia
por: Shinomiya, Shohei, et al.
Publicado: (2021)

Eflapegrastim versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER Studies
por: Moon, Yong Wha, et al.
Publicado: (2023)

Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer
por: Bae, Soong June, et al.
Publicado: (2021)

The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients
por: Wallwiener, Markus, et al.
Publicado: (2015)

A retrospective investigation of the pmx-dhp's efficacy in 88 severe sepsis cases
por: Tanaka, M, et al.
Publicado: (2015)

The Role of Orientation of Surface Bound Dihydropyrrol-2-ones (DHP) on Biological Activity
por: Taunk, Aditi, et al.
Publicado: (2019)

Bioevaluation of superparamagnetic iron oxide nanoparticles (SPIONs) functionalized with dihexadecyl phosphate (DHP)
por: Mieloch, Adam Aron, et al.
Publicado: (2020)

AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20)
por: Suh, Koung Jin, et al.
Publicado: (2023)

Predictive biological factors for late survival in patients with HER2-positive breast cancer
por: Kang, Young-Joon, et al.
Publicado: (2023)

Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP
por: Ji, Jung Hwan, et al.
Publicado: (2022)

An open-label, multicenter, phase I trial of a cremophor-free, polymeric micelle formulation of paclitaxel combined with carboplatin as a first-line treatment for advanced ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3016)
por: Lee, Shin-Wha, et al.
Publicado: (2017)

Talazoparib versus Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial
por: Lee, Kyung-Hun, et al.
Publicado: (2021)

A Standardized Clinical Data Harmonization Pipeline for Scalable AI Application Deployment (FHIR-DHP): Validation and Usability Study
por: Williams, Elena, et al.
Publicado: (2023)

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study
por: Pegram, Mark D., et al.
Publicado: (2018)

Psychometric testing of the Norwegian Diabetes Health Profile (DHP-18) in patients with type 1 diabetes
por: Jelsness-Jørgensen, Lars-Petter, et al.
Publicado: (2018)

PMX-DHP Therapy for Dyspnea and Deoxygenation in Severe COVID-19 Pneumonia: A Case Series
por: Kuwana, Tsukasa, et al.
Publicado: (2021)

BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression
por: Kim, Se Hyun, et al.
Publicado: (2018)

An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021)
por: Lee, Shin-Wha, et al.
Publicado: (2018)

miR-150 enhances apoptotic and anti-tumor effects of paclitaxel in paclitaxel-resistant ovarian cancer cells by targeting Notch3
por: Kim, Tae Hoen, et al.
Publicado: (2017)

Clinical evaluation of endotoxin hemoadsorption therapy (PMX-DHP) for hypercytokinemia caused by septic multiple organ failure
por: Ikeda, T, et al.
Publicado: (2004)

Encapsulation of cathode in lithium-sulfur batteries with a novel two-dimensional carbon allotrope: DHP-graphene
por: Cai, Yingxiang, et al.
Publicado: (2017)

Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results
por: Park, Yeon Hee, et al.
Publicado: (2017)

Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
por: Katuwal, Nar Bahadur, et al.
Publicado: (2023)

PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer
por: Kim, Kui-Jin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mjssh2f5rkljcp0st0j66npd6h